<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00165204</url>
  </required_header>
  <id_info>
    <org_study_id>03-363</org_study_id>
    <nct_id>NCT00165204</nct_id>
  </id_info>
  <brief_title>Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy</brief_title>
  <official_title>A Randomized Study of the Effects of Tibolone on Bone Density, Menopause Symptoms and Breast Density in High Risk Women After Prophylactic Oophorectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <brief_summary>
    <textblock>
      Women undergoing surgical menopause often experience marked menopausal side effects but are&#xD;
      reluctant to use estrogen or other female hormones to ease the transition to menopause&#xD;
      because of worries that the hormones may increase breast cancer risks. This study will&#xD;
      evaluate tibolone in women experiencing surgical menopause to assess its effects on bone&#xD;
      health, menopause symptoms and breast density.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women interested in participating in this study will be allowed to use hormones to manage&#xD;
      symptoms for up to 3 months before beginning the study. Those choosing not to take hormones&#xD;
      may enroll in the study immediately.&#xD;
&#xD;
      All women will have a baseline mammogram, breast examination, and bone study density&#xD;
      performed, along with blood and urine analysis for measurement of bone markers. They will&#xD;
      also be asked to take a questionnaire.&#xD;
&#xD;
      Patients will take either tibolone or placebo once daily for 1 year. Neither the patient or&#xD;
      the physician will be aware of which treatment a woman is taking during the study.&#xD;
&#xD;
      Patients will return at 6 and 12 months to have a physical examination, blood work, urine&#xD;
      collection and bone studies. At one year, a repeat mammogram will be performed. There are&#xD;
      also some questionnaires asking about menopause symptoms that will be performed at intervals&#xD;
      during the study.&#xD;
&#xD;
      It is also recommended that patients take calcium and vitamin D throughout the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare bone mineral density and markers of bone turnover following oophorectomy in patients receiving tibolone versus placebo</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare changes in menopausal symptoms and mammographic breast density in women taking tibolone to women taking placebo</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Menopause</condition>
  <condition>Postmenopausal Bone Loss</condition>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tibolone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Good overall health&#xD;
&#xD;
          -  Premenopausal at the time of enrollment if before their oophorectomy&#xD;
&#xD;
          -  Will undergo or have undergone an oophorectomy&#xD;
&#xD;
          -  Negative breast examination and negative breast imaging studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of breast cancer, ductal carcinoma in situ (DCIS) or other cancer except for&#xD;
             carcinoma in situ of the cervix or basal cell carcinoma of the skin&#xD;
&#xD;
          -  History of ovarian cancer, breast cancer (or DCIS) or other malignancy&#xD;
&#xD;
          -  Low bone mass compared with age-adjusted controls&#xD;
&#xD;
          -  Current or recent exposure (within 3 months) to medications that alter bone metabolism&#xD;
&#xD;
          -  Estrogens, progesterones, androgens, tamoxifen or raloxifene within 3 months of&#xD;
             randomization&#xD;
&#xD;
          -  History of significant medical problems potentially related to estrogens&#xD;
&#xD;
          -  History of Paget's disease of bone, ankylosing spondylitis, rheumatoid arthritis or&#xD;
             other metabolic bone disease, vitamin D deficiency, hyperparathyroidism, or newly&#xD;
             diagnosed hyperthyroidism&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 32&#xD;
&#xD;
          -  High-density lipoprotein (HDL) cholesterol &lt; 40 mg/dl&#xD;
&#xD;
          -  Women whose uterus was retained and who have a history of uterine abnormalities&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judy Garber, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2005</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <keyword>Tibolone</keyword>
  <keyword>High risk women</keyword>
  <keyword>Oophorectomy</keyword>
  <keyword>Breast Density</keyword>
  <keyword>Bone Density</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tibolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

